Loyola Medicine is participating in a clinical trial of a technology called ex vivo lung perfusion (EVLP) that potentially could increase the supply of organs available for lung transplants. EVLP provides a more informed evaluation of lungs that otherwise would be deemed ineligible for transplant. Bob Falat is Loyola's first transplant patient to receive a lung that was evaluated by EVLP. "Everything feels fine," he said. Loyola's lung transplant program is headed by Daniel Dilling, MD, medical director, and Jeffrey Schwartz, MD, surgical director. For more information or to make an appointment, please visit loyolamedicine.org/transplant/lung-transplant or call 888-584-7888.